|Application ||WB, E|
|Other Accession||NP_008859, 6490, 20431 (mouse), 362818 (rat)|
|Calculated MW||70255 Da|
|Other Names||Melanocyte protein PMEL, ME20-M, ME20M, Melanocyte protein Pmel 17, Melanocytes lineage-specific antigen GP100, Melanoma-associated ME20 antigen, P1, P100, Premelanosome protein, Silver locus protein homolog, M-alpha, 95 kDa melanocyte-specific secreted glycoprotein, P26, Secreted melanoma-associated ME20 antigen, ME20-S, ME20S, M-beta, PMEL, D12S53E, PMEL17, SILV|
|Format||0.5 mg IgG/ml in Tris saline (20mM Tris pH7.3, 150mM NaCl), 0.02% sodium azide, with 0.5% bovine serum albumin|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||Goat Anti-Silver homologue / Pmel 17 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Synonyms||D12S53E, PMEL17, SILV|
|Function||Plays a central role in the biogenesis of melanosomes. Involved in the maturation of melanosomes from stage I to II. The transition from stage I melanosomes to stage II melanosomes involves an elongation of the vesicle, and the appearance within of distinct fibrillar structures. Release of the soluble form, ME20-S, could protect tumor cells from antibody mediated immunity.|
|Cellular Location||Endoplasmic reticulum membrane; Single-pass type I membrane protein. Golgi apparatus. Melanosome. Endosome, multivesicular body. Note=Identified by mass spectrometry in melanosome fractions from stage I to stage IV. Localizes predominantly to intralumenal vesicles (ILVs) within multivesicular bodies. Associates with ILVs found within the lumen of premelanosomes and melanosomes and particularly in compartments that serve as precursors to the striated stage II premelanosomes|
|Tissue Location||Preferentially expressed in melanomas. Some expression was found in dysplastic nevi. Not found in normal tissues nor in carcinomas. Normally expressed at low levels in quiescent adult melanocytes but overexpressed by proliferating neonatal melanocytes and during tumor growth|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Endoplasmic reticulum export, subcellular distribution, and fibril formation by Pmel17 require an intact N-terminal domain junction. Leonhardt RM, et al. J Biol Chem, 2010 May 21. PMID 20231267.
The secreted form of a melanocyte membrane-bound glycoprotein (Pmel17/gp100) is released by ectodomain shedding. Hoashi T, et al. FASEB J, 2010 Mar. PMID 19884326.
N-terminal domains elicit formation of functional Pmel17 amyloid fibrils. Watt B, et al. J Biol Chem, 2009 Dec 18. PMID 19840945.
The repeat domain of the melanosome fibril protein Pmel17 forms the amyloid core promoting melanin synthesis. McGlinchey RP, et al. Proc Natl Acad Sci U S A, 2009 Aug 18. PMID 19666488.
Formation of Pmel17 amyloid is regulated by juxtamembrane metalloproteinase cleavage, and the resulting C-terminal fragment is a substrate for gamma-secretase. Kummer MP, et al. J Biol Chem, 2009 Jan 23. PMID 19047044.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.